{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:09:05Z","timestamp":1759334945517,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Mallinckrodt"},{"name":"Corbus"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UCB"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jaad.2020.03.039","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T12:11:37Z","timestamp":1585138297000},"page":"e27-e28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reply to: \u201cEvidence-based guidelines for tuberculosis screening before biologic treatment initiation\u201d"],"prefix":"10.1016","volume":"83","author":[{"given":"Anthony P.","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariana","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urmi","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AbdulAziz","family":"Galadari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2020.03.039_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaad.2018.03.025","article-title":"Low conversion rate of QuantiFERON-TB Gold screening tests in patients treated with tumor necrosis factor inhibitors: a retrospective cohort study identifying an important practice gap","volume":"79","author":"Chung","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.03.039_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaad.2020.01.012","article-title":"Conversion to positive latent tuberculosis infection status is low in hidradenitis suppurativa patients taking biologic medications","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2020.03.039_bib3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/acr2.11070","article-title":"Conversion of tuberculosis screening tests during biologic therapy among veteran patient population with rheumatic disease","volume":"1","author":"Pattanaik","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.jaad.2020.03.039_bib4","unstructured":"Healthmonix. 2019 MIPS Measure #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier. http:\/\/healthmonix.com\/mips_quality_measure\/2019-mips-quality-measure-337\/. Accessed March 12, 2020."},{"key":"10.1016\/j.jaad.2020.03.039_bib5","unstructured":"Unites Heathcare. Specialty Medication Prior Authorization Cover Sheet. https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/prior-auth\/uhccp-pharmacy-forms\/h-l\/MI-Humira-Prior-Authorization-Form.pdf. Accessed March 12, 2020."},{"key":"10.1016\/j.jaad.2020.03.039_bib6","unstructured":"CareSource. Pharmacy Policy Statement: Ohio Medicaid. https:\/\/www.caresource.com\/documents\/medicaid-oh-policy-pharmacy-adalimumab-20190401\/. Accessed March 12, 2020."},{"issue":"suppl 10","key":"10.1016\/j.jaad.2020.03.039_bib7","article-title":"Utility of repeat latent tuberculosis testing in patients taking biologics [abstract]","volume":"71","author":"Khanna","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"15","key":"10.1016\/j.jaad.2020.03.039_bib8","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/jama.2019.13978","article-title":"Waste in the US health care system: estimated costs and potential for savings","volume":"322","author":"Shrank","year":"2019","journal-title":"JAMA"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222030459X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222030459X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:56:32Z","timestamp":1759272992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222030459X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S019096222030459X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.03.039","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to: \u201cEvidence-based guidelines for tuberculosis screening before biologic treatment initiation\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.02.084","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}